Method for determining the prognosis of cancer patients by measuring levels of bag expression
AssigneeThe Burnham Institute
InventorJohn C. Reed
Life of this patent
Estimating the term…
Abstract
In accordance with the present invention, there are provided methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. Also provided are methods for predicting the risk of tumor recurrence or spread in an individual having a cancer tumor. Methods for screening a cancer patient to determine the risk of tumor metastasis; methods for determining the proper course of treatment for a patient suffering from cancer; and kits for use in practicing the invention methods.
Claims32
1-50. (canceled)
A method for prognosis of disease-free or overall survival of an individual having node-positive breast cancer, wherein said individual has not received adjuvant chemotherapy, comprising determining the level of BAG-1 expression in infiltrating cells of a sample of tumor or infiltrating tumor cells from a body fluid of said patient, wherein a high level of BAG-1 expression relative to a reference level of BAG-1 expression correlates positively with disease-free or overall survival.
A method for predicting the risk of tumor recurrence or spread in an individual having a node-positive breast cancer tumor, wherein said individual has not received adjuvant chemotherapy, comprising determining the level of BAG-1 expression in infiltrating cells of a sample of said tumor or infiltrating breast tumor cells from a body fluid from said individual, wherein a high level of BAG-1 expression relative to a reference level of BAG-1 expression correlates negatively with tumor recurrence or spread.
A method for screening a patient with node-positive breast cancer, wherein said patient has not received adjuvant chemotherapy, to determine the risk of tumor metastasis or chance of survival, said method comprising:
- (a) determining the level of expression of BAG-1 expression in infiltrating cells of a cancerous tissue sample or infiltrating tumor cells from a body fluid sample from said patient;
- and
- (b) classifying a patient having high levels of expression of BAG-1 protein, relative to a reference level, as being less likely to suffer tumor metastasis or having an increased chance of survival.
A method for determining the proper course of treatment for a patient suffering from node-positive breast cancer, wherein said patient has not received adjuvant chemotherapy, said method comprising:
- (a) determining the level of BAG-1 expression in infiltrating cells of a cancerous tissue sample or infiltrating tumor cells from a body fluid from said patient;
- (b) identifying a first group of patients having low levels of BAG-1 expression relative to a reference level of BAG-1 expression, which first group of patients may require treatment proper for patients having a lesser chance of survival or being more likely to suffer tumor recurrence or spread;
- and
- (c) identifying a second group of patients having high levels of BAG-1 expression relative to a reference level of BAG-1 expression, which second group of patients may require treatment proper for patients having a greater chance of survival and being less likely to suffer tumor recurrence or spread.
A method for determining risk of tumor recurrence or spread in a patient suffering from a node-positive breast cancer, wherein said patient has not received adjuvant chemotherapy, said method comprising:
- (a) determining the level of expression of BAG-1 expression in infiltrating cells of a cancerous tissue of the patient;
- and
- (b) classifying said patient as belonging either to a first group of patients having high levels of expression of BAG-1 relative to a reference level of BAG-1 expression, or a second group of patients having low levels of expression of BAG-1 relative to a reference level of BAG-1 expression,
- wherein said first group has a lower likelihood of tumor recurrence or spread than said second group, thereby determining a lower risk of tumor recurrence or spread in the first group of patients suffering from breast cancer.
Dependencies are inferred from the claim text.